Your browser is no longer supported. Please, upgrade your browser.
Settings
AGN Allergan plc daily Stock Chart
AGN [NYSE]
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-13.47 Insider Own0.10% Shs Outstand342.92M Perf Week-2.80%
Market Cap52.81B Forward P/E9.21 EPS next Y16.73 Insider Trans-16.83% Shs Float338.19M Perf Month-4.07%
Income-4501.80M PEG- EPS next Q4.09 Inst Own88.50% Short Float1.46% Perf Quarter-7.09%
Sales16.04B P/S3.29 EPS this Y-543.10% Inst Trans0.31% Short Ratio1.58 Perf Half Y-11.91%
Book/sh216.16 P/B0.71 EPS next Y4.35% ROA-1.80% Target Price207.35 Perf Year-31.36%
Cash/sh5.93 P/C25.99 EPS next 5Y6.75% ROE-3.00% 52W Range142.81 - 256.80 Perf YTD-5.86%
Dividend2.88 P/FCF11.13 EPS past 5Y15.01% ROI-2.10% 52W High-40.03% Beta1.14
Dividend %1.87% Quick Ratio0.90 Sales past 5Y21.90% Gross Margin86.00% 52W Low7.84% ATR4.22
Employees17800 Current Ratio1.10 Sales Q/Q2.80% Oper. Margin-23.30% RSI (14)47.20 Volatility2.04% 2.75%
OptionableYes Debt/Eq0.37 EPS Q/Q87.30% Profit Margin-13.10% Rel Volume0.41 Prev Close153.66
ShortableYes LT Debt/Eq0.36 EarningsApr 30 BMO Payout- Avg Volume3.12M Price154.00
Recom2.20 SMA200.68% SMA50-3.23% SMA200-14.23% Volume1,271,118 Change0.22%
Apr-24-18Resumed Citigroup Buy $200
Apr-23-18Resumed Evercore ISI Outperform
Apr-17-18Initiated Stifel Hold $192
Feb-23-18Initiated SunTrust Buy $200
Feb-07-18Reiterated Leerink Partners Outperform $237 → $242
Dec-07-17Downgrade Argus Buy → Hold
Nov-29-17Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-27-17Resumed Leerink Partners Outperform $237
Nov-02-17Reiterated RBC Capital Mkts Outperform $250 → $221
Oct-19-17Reiterated RBC Capital Mkts Outperform $277 → $250
Oct-17-17Reiterated UBS Buy $275 → $255
Oct-02-17Reiterated Barclays Equal Weight
Sep-25-17Reiterated RBC Capital Mkts Outperform $285 → $277
Sep-20-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-17Initiated Cantor Fitzgerald Neutral $231
Jun-09-17Reiterated Mizuho Buy $275 → $267
May-10-17Reiterated RBC Capital Mkts Outperform $279 → $284
May-10-17Downgrade Goldman Buy → Neutral
Feb-09-17Reiterated Mizuho Buy $273 → $275
Dec-09-16Reiterated Credit Suisse Outperform $301 → $274
May-23-18 10:51AM  Allergan Stock Down Since Q1 Earnings Report: Here's Why Zacks
May-22-18 05:31PM  Allergan plc (NYSE:AGN): Has Recent Earnings Growth Beaten Long-Term Trend? Simply Wall St.
08:00AM  Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration PR Newswire
07:38AM  Jim Cramer Weighs In On Royal Caribbean Cruises, Allergan And More Benzinga
May-21-18 07:05PM  Cramer's lightning round: The bears are wrong about cruis... CNBC Videos
06:51PM  Cramer's lightning round: The bears are wrong about cruise ship stocks CNBC
05:59PM  Business Highlights Associated Press
09:43AM  Dispute on eye drop size fails to catch Supreme Court's eye Associated Press
May-18-18 10:56AM  Top Research Reports for Walmart, AT&T & Novo Nordisk Zacks
09:57AM  David Tepper gets US approval to take activist stance on Allergan, if he wants it CNBC
08:20AM  Today's Research Reports on Trending Tickers: Amgen and Allergan ACCESSWIRE
May-17-18 08:00PM  Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI TheStreet.com
06:43PM  Appaloosa gets permission for activist stance with Allergan stake Reuters
04:18PM  Allergan's Meury Talks Market Expansion in Aesthetics TheStreet.com
10:53AM  Walmart under pressure, Allergan's up, Alphabet dips Yahoo Finance
10:40AM  Walmart, Allergan and Alphabet are the Yahoo Finance charts of the day. Yahoo Finance Video
May-16-18 05:58PM  Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug Reuters
04:15PM  Allergan to Present at the Bernstein Strategic Decisions Conference PR Newswire
02:27PM  Evolus investors frown as FDA declines to approve Botox rival Reuters
11:13AM  Why Evolus, Inc. Is Crashing Today Motley Fool
11:07AM  Evolus investors frown as FDA declines to approve Botox rival Reuters
08:43AM  FDA declines to approve Evolus Inc's rival treatment to Botox Reuters
May-14-18 02:04PM  Big Pay, Little Return Yahoo Finance Video
08:04AM  [$$] CEO Pay and Performance Often Don't Match Up The Wall Street Journal
May-10-18 02:58PM  MARKETS: Biotech and pharma stocks could be the key to the market bull case Yahoo Finance Video
May-09-18 08:43PM  6 Days Left To Allergan plc (NYSE:AGN)s Ex-Dividend Date, Is It Worth Buying? Simply Wall St.
11:59AM  Musk Meltdown Underscores Art of Keeping Earnings Calls Dull Bloomberg
11:59AM  How Companies Keep Most Earnings Calls So Incredibly Boring Bloomberg
10:13AM  Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate Benzinga
08:57AM  How $6 billion generic drug company merger could affect this East Bay city and Roche American City Business Journals
May-08-18 04:55PM  Allergan Expects to Finish Strategic Review Quickly, CFO Says TheStreet.com
10:33AM  Get Ready for 'Brotox' Bloomberg
03:45AM  Takeda Finally Inks a Deal to Buy Shire in One of the Biggest Pharma Takeovers Ever Fortune
May-07-18 04:15PM  Allergan to Present at the Bank of America Merrill Lynch Healthcare Conference PR Newswire
May-04-18 04:06PM  Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication Zacks
May-03-18 05:00PM  John Davidson Elected to Allergan Board of Directors PR Newswire
04:30PM  Allergan Declares Second Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share PR Newswire
04:05PM  Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation Business Wire
May-02-18 11:00AM  Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring Zacks
08:00AM  Allergan to Present Data from a Robust Mental Health Clinical Program at the American Psychiatric Association (APA) 2018 Annual Meeting PR Newswire
07:00AM  Botox Makes Allergan Worth a Shot Morningstar
May-01-18 10:41PM  Edited Transcript of AGN earnings conference call or presentation 30-Apr-18 12:30pm GMT Thomson Reuters StreetEvents
09:45PM  [$$] Ironwood Will Separate From Its Rare-Disease Drug Unit After Pressure The Wall Street Journal
04:15PM  Allergan to Present at the Deutsche Bank 43rd Annual Health Care Conference PR Newswire
04:01PM  Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action PR Newswire
02:49PM  Allergan CEO Says Splitting Company Among Options Under Review Bloomberg Video
02:48PM  Allergan CEO Says Splitting Company Among Options Under Review Bloomberg
08:57AM  Pfizer Shares Deflate After Another Quarter Without a Big Transaction Fortune
08:20AM  Today's Research Reports on Trending Tickers: Gilead Sciences and Allergan ACCESSWIRE
06:25AM  Allergan: Cramer's Top Takeaways TheStreet.com
Apr-30-18 07:06PM  New depression drug could be 'absolute game-changer': All... CNBC Videos -5.18%
07:06PM  Cramer Remix: The world has turned on this sector CNBC Videos
06:59PM  Cramer Remix: The world has turned on this sector CNBC
06:51PM  Allergan CEO says new depression drug could be an 'absolu... CNBC Videos
06:22PM  Allergan CEO says Botox maker's new depression drug could be an 'absolute game-changer' CNBC
04:49PM  US STOCKS-Wall St slides as healthcare drags but manages monthly gain Reuters
04:34PM  Allergan Beats Quarterly Views, But Dips On Report It's 'Unlikely' To Make A Deal Investor's Business Daily
03:49PM  Allergan Is Still In a Downtrend as We Wait for a Bottom to Form TheStreet.com
02:32PM  Allergan's Q1 Earnings: What You Need to Know Motley Fool
01:19PM  Allergan Slides With Wall Street Fearing Management Will Do Nothing Bloomberg
01:18PM  Allergan plc Earnings: 10 Things to Know InvestorPlace
01:11PM  Allergan Is Betting on Botox for Men Bloomberg
12:50PM  Should You Buy Allergan plc (NYSE:AGN) At $162.04? Simply Wall St.
12:46PM  These big pharma names report earnings tomorrow CNBC Videos
12:39PM  Heres What Just Happened At Allergan Market Exclusive
12:32PM  Allergan plc (AGN) Q1 2018 Earnings Conference Call Transcript Motley Fool
12:24PM  Allergan CEO opposes fundamental shift in strategy, shares fall Reuters
12:05PM  US STOCKS-Wall St edges higher on strong McDonald's earnings, health drags Reuters
11:58AM  Allergan CEO opposes fundamental shift in strategy, shares fall Reuters
11:56AM  Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y Zacks
11:43AM  Allergan May Need More Than a Facelift Bloomberg
10:56AM  Allergan CEO opposes fundamental shift in strategy, shares dip Reuters
09:18AM  Allergan CEO: large deal would be an unlikely outcome of review Reuters
09:09AM  US STOCKS-Wall St set for gains on strong earnings, M&A activity Reuters
08:41AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
08:30AM  US STOCKS-Futures rise on strong earnings, M&A activity Reuters
08:30AM  Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study PR Newswire
07:42AM  Allergan (AGN) Beats Q1 Earnings, Stock Up Zacks
07:14AM  Allergan's stock surges after profit, revenue beat expectations MarketWatch
07:08AM  Botox-maker Allergan quarterly revenue rises 2.8 pct Reuters
07:00AM  Allergan Reports 3% Increase in First Quarter 2018 GAAP Net Revenues to $3.7 Billion PR Newswire
06:00AM  Allergan plc to Host Earnings Call ACCESSWIRE
Apr-27-18 07:11PM  This market lacks clarity. Here's how to manage CNBC Videos
06:39PM  Cramer's game plan: This market lacks clarity. Here's how... CNBC Videos
06:23PM  Cramer's game plan: This market lacks clarity. Here's how to manage CNBC
04:52PM  What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week TheStreet.com
04:11PM  Allergan's Next Strategic Move Is Key Focus Ahead of Earnings Bloomberg
02:33PM  NYSE trader earnings preview: Apple, McDonald's, Tesla and Alibaba Yahoo Finance Video
10:38AM  Allergan migraine drug succeeds in second late-stage trial Reuters
10:04AM  Allergan Unveils Positive Data for New Migraine Drug TheStreet.com
08:00AM  Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant -- an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine PR Newswire
Apr-26-18 05:01PM  Allergan to Present New Data at the American College of Obstetrics and Gynecology 67th Annual Clinical and Scientific Meeting 2018 PR Newswire
08:36AM  Why Earnings Season Could Be Great for Allergan (AGN) Zacks
08:01AM  Allergan Presents Data at the Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO) Annual Meeting in Honolulu PR Newswire
Apr-25-18 12:25PM  Shire willing to back $64 billion Takeda bid, market signals doubts Reuters
08:30AM  Today's Research Reports on Trending Tickers: Allergan and Incyte Corporation ACCESSWIRE
Apr-24-18 09:55PM  Supreme Court upholds legality of patent review process Reuters
04:56PM  U.S. Supreme Court upholds legality of patent review process Reuters
11:29AM  U.S. Supreme Court upholds legality of patent review process Reuters
10:10AM  U.S. Supreme Court upholds legality of patent review process Reuters
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meury WilliamEVP & Chief Commercial OfficerMay 17Option Exercise68.1121,2521,447,47440,154May 21 05:21 PM
Meury WilliamEVP & Chief Commercial OfficerMay 17Sale154.5924,4253,775,86115,729May 21 05:21 PM
Hilado Maria TeresaExecutive Vice PresidentMar 15Buy167.39895149,81426,530Mar 19 09:36 AM
WALSH MATTHEW MEVP, Chief Financial OfficerMar 08Buy153.961,000153,96025,416Mar 08 10:44 AM
SAUNDERS BRENT LChairman, President and CEOMar 08Buy152.533,300503,349180,931Mar 08 10:25 AM
Boccuzi Joseph HDirectorMar 05Buy143.42900129,0781,862Mar 09 04:31 PM
WALSH MATTHEW MEVP, Chief Financial OfficerFeb 21Buy160.942,000321,88024,416Feb 22 04:25 PM
Meury WilliamChief Commercial OfficerFeb 14Option Exercise63.1723,6131,491,73778,600Feb 16 05:10 PM
Meury WilliamChief Commercial OfficerFeb 14Sale160.6258,8799,457,36919,721Feb 16 05:10 PM
BODINE CHRIS WDirectorDec 07Buy164.773,030499,25317,098Dec 07 05:21 PM
SAUNDERS BRENT LChairman, President and CEODec 06Buy164.744,600757,794186,377Dec 06 12:31 PM
COUGHLIN CHRISTOPHER JDirectorDec 05Buy163.3010,0001,633,00014,446Dec 05 04:16 PM
Meury WilliamChief Commercial OfficerDec 01Option Exercise78.8811,807931,33668,828Dec 04 06:21 PM
Meury WilliamChief Commercial OfficerDec 01Sale173.8911,8072,053,11957,021Dec 04 06:21 PM
SAUNDERS BRENT LChairman, President and CEOJun 16Buy235.964410,327131,178Sep 18 08:49 PM